we may not have all the data yet, but limiting access could be counterproductive
- Written by Kylie Quinn, Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
Last week, a German vaccine advisory committee recommended the AstraZeneca vaccine only be used in 18-64-year-olds, citing a lack of data on the efficacy of the vaccine in people over 65.
Subsequently, the European regulator, the European Medicines Agency, conditionally approved the vaccine for anyone over 18.
What can we make of this? Should we be...





